Actinium Pharmaceuticals
ATNM
50 hedge funds and large institutions have $11.9M invested in Actinium Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 4 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
112% more call options, than puts
Call options by funds: $3.47M | Put options by funds: $1.64M
32% more funds holding
Funds holding: 38 → 50 (+12)
27% more capital invested
Capital invested by funds: $9.37M → $11.9M (+$2.54M)
2.13% more ownership
Funds ownership: 8.28% → 10.4% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 2 |
Renaissance Technologies
New York
|
+$328K |
| 3 |
Two Sigma Investments
New York
|
+$325K |
| 4 |
Millennium Management
New York
|
+$188K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$181K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$110K |
| 2 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$33K |
| 3 |
D.E. Shaw & Co
New York
|
-$32.4K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$14.8K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$5.68K |
ATNM Hedge Fund Activity: Q2 2022 in Review
50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2022, worth a combined $11.9M — up 27% from $9.37M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ATNM positions and 4 closed out — a net gain of 13 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.19M. The largest seller was Simplex Trading, exiting entirely with an estimated $110K sold.
- 50 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2022, up from 38 in Q1 2022.
- Funds reported $11.9M of Actinium Pharmaceuticals stock for Q2 2022, up 27% quarter-over-quarter.
- 17 funds opened new Actinium Pharmaceuticals positions in Q2 2022 and 4 closed out, a net change of +13 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2022 was Vanguard Group, an estimated $1.19M added.
- The largest Actinium Pharmaceuticals seller in Q2 2022 was Simplex Trading, an estimated $110K sold.
Based on aggregated 13F filings for Q2 2022.